The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Dr. Graeme M. Rosenberg, a thoracic surgeon specializing in airway intervention and reconstruction, and Dr. Jorge J. Nieva, an affiliate professor of...
The U.S. Meals and Drug Administration (FDA) just lately introduced that it had granted a nationwide precedence overview voucher to Tecvayli (teclistamab)...
